Antineoplastics
1
Reactions 1425 - 27 Oct 2012 S Antineoplastics Neutropenia, elevated alanine aminotransferase levels and peripheral neuropathy: 6 case reports In a retrospective study of 24 lymphoma patients, six patients were identified after they developed adverse events, including neutropenia, elevated ALT levels and peripheral neuropathy, that were associated with antineoplastic treatment [times to onset and some outcomes not stated]. Four men and two women, aged 29–67 years, were diagnosed with non-conjunctival ocular mucosa-associated lymphoid tissue-type (MALT) lymphoma. Two patients received CVP chemotherapy for six cycles, consisting of IV cyclophosphamide 750 mg/m 2 for more than 30 minutes on day 1, an IV bolus of vincristine 1.4 mg/m 2 (maximum 2mg) on day 1, and oral prednisone 60 mg/m 2 on days 1–5. Another two patients received either three or six cycles of CHOP chemotherapy, consisting of cyclophosphamide and vincristine as for CVP chemotherapy, IV doxorubicin 50 mg/m 2 on day 1 and oral prednisone 60mg on days 1–5. The remaining two patients received either six cycles of R- CHOP or eight cycles of R-CVP chemotherapy, for which IV rituximab 375 mg/m 2 [frequencies not stated] was added to the CHOP or CVP regimen, respectively. Treatment cycles were administered every 3 weeks. Two women developed grade 3 neutropenia associated with either R-CHOP or CVP chemotherapy. They both recovered without neutropenic fever. Grade 1 ALT level increases occurred in two patients receiving either R-CHOP or R-CVP chemotherapy; one of these patients had also developed neutropenia. The three remaining men experienced grade 2 peripheral neuropathy during either CHOP or CVP treatment. One of these patients could not complete his scheduled CHOP chemotherapy, and was switched to radiotherapy. Author comment: "Toxic effects associated with combination chemotherapy are hematologic complications such as neutropenia and anemia, and non-hematologic complications such as elevated ALT and paresthesia, which develop from alkylating agents." Paik J-S, et al. Ophthalmologic outcomes after chemotherapy and/or radiotherapy in non-conjunctival ocular adnexal MALT lymphoma. Annals of Hematology 91: 1393-1401, No. 9, Sep 2012. Available from: URL: http://dx.doi.org/10.1007/ s00277-012-1469-3 - South Korea 803078986 1 Reactions 27 Oct 2012 No. 1425 0114-9954/10/1425-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1425 - 27 Oct 2012
SAntineoplastics
Neutropenia, elevated alanine aminotransferaselevels and peripheral neuropathy: 6 case reports
In a retrospective study of 24 lymphoma patients, sixpatients were identified after they developed adverseevents, including neutropenia, elevated ALT levels andperipheral neuropathy, that were associated withantineoplastic treatment [times to onset and someoutcomes not stated].
Four men and two women, aged 29–67 years, werediagnosed with non-conjunctival ocular mucosa-associatedlymphoid tissue-type (MALT) lymphoma. Two patientsreceived CVP chemotherapy for six cycles, consisting of IVcyclophosphamide 750 mg/m2 for more than 30 minuteson day 1, an IV bolus of vincristine 1.4 mg/m2 (maximum2mg) on day 1, and oral prednisone 60 mg/m2 on days 1–5.Another two patients received either three or six cycles ofCHOP chemotherapy, consisting of cyclophosphamide andvincristine as for CVP chemotherapy, IV doxorubicin50 mg/m2 on day 1 and oral prednisone 60mg on days 1–5.The remaining two patients received either six cycles of R-CHOP or eight cycles of R-CVP chemotherapy, for which IVrituximab 375 mg/m2 [frequencies not stated] was added tothe CHOP or CVP regimen, respectively. Treatment cycleswere administered every 3 weeks. Two women developedgrade 3 neutropenia associated with either R-CHOP or CVPchemotherapy. They both recovered without neutropenicfever. Grade 1 ALT level increases occurred in two patientsreceiving either R-CHOP or R-CVP chemotherapy; one ofthese patients had also developed neutropenia. The threeremaining men experienced grade 2 peripheral neuropathyduring either CHOP or CVP treatment. One of thesepatients could not complete his scheduled CHOPchemotherapy, and was switched to radiotherapy.
Author comment: "Toxic effects associated withcombination chemotherapy are hematologic complicationssuch as neutropenia and anemia, and non-hematologiccomplications such as elevated ALT and paresthesia, whichdevelop from alkylating agents."Paik J-S, et al. Ophthalmologic outcomes after chemotherapy and/or radiotherapyin non-conjunctival ocular adnexal MALT lymphoma. Annals of Hematology 91:1393-1401, No. 9, Sep 2012. Available from: URL: http://dx.doi.org/10.1007/s00277-012-1469-3 - South Korea 803078986
1
Reactions 27 Oct 2012 No. 14250114-9954/10/1425-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
